Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.01 USD | -0.98% | -4.72% | -26.81% |
Apr. 30 | In8bio, Inc. Doses First Patient in Phase 2 Clinical Trial of Inb-400 in Newly Diagnosed Glioblastoma | CI |
Apr. 10 | Top Premarket Gainers | MT |
- Stock Market
- Equities
- INAB Stock
- News IN8bio, Inc.
- MarketScreener Editorial Features